Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Renal Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1453668
This article is part of the Research Topic Diabetic Kidney Disease: Routes to drug development, pharmacology and underlying molecular mechanisms, Volume II View all 12 articles

Shenshuaikang enema restores the intestinal barrier and microbiotagut-kidney axis balance to alleviate chronic kidney disease via NF-kB pathway

Provisionally accepted
艳 叶 艳 叶 1,2Xiaopeng Huang Xiaopeng Huang 1,2,3*Xueying Li Xueying Li 1,4*Wenzhen Zhong Wenzhen Zhong 5Anqi Tang Anqi Tang 1,2Liangbin Zhao Liangbin Zhao 1*Dengpiao Xie Dengpiao Xie 1*Naijing Ye Naijing Ye 1,2
  • 1 Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
  • 2 TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
  • 3 Department of Ministry of Science, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
  • 4 School of Clinical Medicine, Chengdu University of Traditional Chinses Medicine, Chengdu, Sichuan Province, China
  • 5 State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Introduction: Chronic kidney disease (CKD) is a chronic progressive disease characterized by abnormalities in kidney structure or function caused by variousfactors. It has become a significant public health problem, posing a threat to human health worldwide. Shenshuaikang enema (SSKE) has demonstrated notable efficacy and safety in treating CKD, although its mechanism of action remains unclear.The CKD rat model was induced using 2.5% adenine, and the effect of SSKE was evaluated by detecting uremic toxins, inflammatory cytokines, and renal function. The structure of the intestine and kidney was observed using electron microscopy. Pathological changes in the intestine and kidney were detected by H&E staining. The expression of Occludin, Claudin-1, and ZO-1 in the intestine was detected by immunohistochemistry. The degree of renal fibrosis was observed using Masson and PAS staining. The expression of NF-B and MyD88 protein in the intestine, and the expression of F4/80, TLR4, NF-B and MyD88 in the kidney were detected by immunofluorescence staining. NF-κB-RE-Luc transgenic mice were used to construct a CKD mouse model, and changes in fluorescence intensity in mice and isolated kidney tissues were detected within 1-6 days using a small animal live imager. Finally, 16S rRNA amplicon sequencing was used to monitor changes in intestinal flora in CKD patients before and after SSKE treatment.We found that SSKE improves renal function, attenuates renal fibrosis, reduces inflammatory factor levels, and decreases damage to intestinal and renal structures in adenineinduced CKD rats. Additionally, our results suggest that SSKE regulates NF-κB pathways, increases the expression of tight junction proteins, improves intestinal permeability, promotes the growth of beneficial bacteria, inhibits the proliferation of harmful bacteria, and reduces metabolic disorders. Ultimately, these effects contribute to the efficacy of SSKE in treating CKD.These results indicate that SSKE restores intestinal barrier function by regulating the microbiota-gut-kidney axis, thereby treating CKD.

    Keywords: Chronic kidney disease (CKD), shenshuaikang enema (SSKE), microbiota-gutkidney axis, NF-B pathway, intestinal barrier

    Received: 23 Jun 2024; Accepted: 19 Nov 2024.

    Copyright: © 2024 叶, Huang, Li, Zhong, Tang, Zhao, Xie and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaopeng Huang, TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Xueying Li, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Liangbin Zhao, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
    Dengpiao Xie, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.